Nurix Therapeutics
1700 Owens Street
Suite 205
San Francisco
California
94158
United States
Tel: 415-660-5320
Website: https://www.nurixtx.com/
Email: Info@nurix-inc.com
About Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
128 articles about Nurix Therapeutics
-
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Nurix Therapeutics, Inc. today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.
-
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
12/15/2022
Nurix Therapeutics, Inc. announced that it has received clearance from the U.S. Food and Drug Administration for the company's Investigational New Drug application to expand the ongoing Phase 1 clinical program for NX-5948 into sites in the United States.
-
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
12/12/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by Anthony Mato, M.D., MSCE, former director of the Chronic Lymphocytic (CLL) Program at Memorial Sloan Kettering Cancer Center, and Omar Abdel-Wahab, M.D., Chair of Sloan Kettering Institute (SKI) Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center.
-
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
12/7/2022
Nurix Therapeutics, Inc. announced that it will host a live webcast to review clinical data from the Phase 1 clinical trial of its leading BTK degrader program, NX-2127, at 8:30 pm CT on Monday, December 12, 2022.
-
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
11/10/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607.
-
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
11/10/2022
Nurix Therapeutics, Inc. presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 – 12th in Boston.
-
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
11/3/2022
Nurix Therapeutics, Inc. announced that its clinical-stage BTK degrader programs will be featured in two oral presentations and one poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held December 10-13, 2022 in New Orleans, LA.
-
Nurix Therapeutics to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November:.
-
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
10/26/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of new preliminary clinical data comprised of a case study of a patient with aggressive non-germinal center B-cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
-
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
10/19/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, at the 5th Annual TPD Summit which is being held October 25‒28, 2022, in Boston, MA.
-
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
10/6/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update.
-
Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10/5/2022
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, announced six poster presentations at the upcoming Society for Immunotherapy of Cancer’s 37th Annual Meeting which is being held November 8 – 12th in Boston.
-
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
9/14/2022
Nurix Therapeutics, Inc. today announced the appointment of Edward C. Saltzman to its board of directors.
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences
8/31/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September.
-
New chief executive officers take the reins of companies, while chief financial officers step into their roles overseeing the finances of respective businesses and more.
-
Nurix Therapeutics Announces $40 Million Registered Direct Offering
7/8/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, pre-funded warrants to purchase 2,869,440 shares of common stock.
-
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
7/7/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the second quarter ended May 31, 2022 and provided a corporate update.
-
Nurix Therapeutics Announces $55 Million Registered Direct Offering
7/7/2022
Nurix Therapeutics, Inc. announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a registered direct offering, pre-funded warrants to purchase 3,945,480 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $55 million, before deducting estimated offering expenses.
-
Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
6/30/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company's Investigational New Drug (IND) application to expand the ongoing Phase 1 clinical program for NX-1607 into sites in the United States.
-
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress
6/10/2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress.